PIK3CB
PIK3CB is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Overview
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signalling cascades involved in cell growth, survival, proliferation, motility and morphology.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Doxorubicin. Open Targets scores its association with cancer at 0.82 (direct and indirect evidence; datatypes clinical 0.67, affected pathway 0.86, literature 0.99, genetic association 0.31, somatic mutation 0.86, animal model 0.39). IntOGen calls it a driver in 5 cohorts (4 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma, Glioblastoma Multiforme, Prostate Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PIK3CB is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 1 · What it is
PIK3CB is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 2 · What goes wrong in cancer
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides.
- 3 · How drugs use it
No product in this corpus aims at PIK3CB yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:8976 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42338 (protein name, function text, keywords and locations (REST API)); CIViC gene PIK3CB (2 evidence items, 0 assertions, 2 variants; diseases: Sarcoma (GraphQL API, CC0)); Open Targets ENSG00000051382 (association with cancer (MONDO_0004992) 0.82; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.51, ovarian cancer 0.51, head and neck squamous cell carcinoma 0.50, skin cancer 0.55, breast cancer 0.67, lung cancer 0.54 (GraphQL API, CC0)); IntOGen PIK3CB (driver in 5 cohorts (Act 4, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signalling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G protein-coupled receptor (GPCR) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signalling pathways for stable platelet adhesion and aggregation. Location: Cytoplasm; Nucleus (UniProt). Locus 3q22.3 (HGNC).
- Breast cancer: Open Targets association 0.67 with breast cancer (MONDO_0007254)
- Sarcomas: CIViC evidence names this disease
- Prostate cancer: IntOGen driver in 2 cohorts (PRAD)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.54 with lung cancer (MONDO_0008903)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.67; IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PIK3CB" OR ABSTRACT:"PIK3CB" OR TITLE:"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta" OR ABSTRACT:"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta" OR TITLE:"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform" OR ABSTRACT:"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform" OR TITLE:"PIK3C1" OR ABSTRACT:"PIK3C1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PIK3CB, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNOTCH2
Shares Lung cancer (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).
- TargetRAD51B
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetNCOR1
Shares Lung cancer (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).
- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetLRP1B
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetMECOM
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetFANCA
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetARHGAP35
Shares Lung cancer (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).